THERAPY OF ENDOCRINE DISEASE: Steroidogenesis enzyme inhibitors in Cushing's syndrome | Zendy

Eleni Daniel | Zendy; John NewellPrice | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

THERAPY OF ENDOCRINE DISEASE: Steroidogenesis enzyme inhibitors in Cushing's syndrome

Author(s) -

Eleni Daniel,

John NewellPrice

Publication year - 2015

Publication title -

european journal of endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.897

H-Index - 148

eISSN - 1479-683X

pISSN - 0804-4643

DOI - 10.1530/eje-14-1014

Subject(s) - metyrapone , ketoconazole , medicine , mitotane , aminoglutethimide , endocrine disease , endocrine system , endocrinology , disease , cushing syndrome , adrenocortical carcinoma , hormone , dermatology , antifungal , cancer , breast cancer , aromatase

Steroidogenesis enzyme inhibitors are the mainstay of medical therapy in Cushing's syndrome (CS). Ketoconazole (KTZ) and metyrapone are the most commonly used agents. Although there is considerable experience of their use in individual specialist centres, these drugs have not been rigorously tested in prospective clinical trials. Clinicians face uncertainties and concerns with respect to the safety profile of these agents, and best means to monitor effect. We review steroidogenesis inhibitors in the management of CS, including older agents (KTZ, metyrapone, etomidate and mitotane) and those currently under development (LCI699, non-racemic KTZ), and offer a practical approach for their use in clinical practice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research